Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Doxazosin
Drug ID BADD_D00718
Description Doxazosin is an alpha-1 antagonist used for the treatment of benign prostatic hypertrophy (BPH) symptoms and hypertension. Other members of this drug class include [Prazosin], [Terazosin], [Tamsulosin], and [Alfuzosin].[A180661] Because of its long-lasting effects, doxazosin can be administered once a day.[A180649] It is marketed by Pfizer and was initially approved by the FDA in 1990.[L7285]
Indications and Usage For treatment and management of mild to moderate hypertension and urinary obstruction symptoms caused by BPH.
Marketing Status Prescription; Discontinued
ATC Code C02CA04
DrugBank ID DB00590
KEGG ID D07874
MeSH ID D017292
PubChem ID 3157
TTD Drug ID D03MIR
NDC Product Code 0049-2614; 23155-092; 68071-4272; 50090-3927; 42291-259; 70518-2183; 68071-4892; 16729-415; 68382-784; 68788-7149; 70518-1560; 50090-0704; 0049-2040; 70518-1804; 70934-362; 68071-5153; 16729-414; 65427-018; 71610-043; 66267-377; 50090-5773; 70771-1112; 50090-0734; 0904-5523; 16729-213; 60505-0093; 68788-7328; 60505-0094; 68084-862; 43063-739; 59762-2420; 16729-211; 71335-0309; 23155-095; 63629-7891; 68382-785; 59762-2410; 50090-2153; 59762-2480; 71610-628; 68084-836; 71335-0002; 55154-7996; 0049-2410; 70934-921; 71610-153; 50090-0701; 23155-094; 68071-3298; 42291-258; 70771-1113; 0049-2512; 0904-5522; 68084-851; 50090-4000; 50090-4004; 23155-093; 42291-260; 60505-0096; 68382-786; 0904-5524; 50090-5540; 60505-0095; 50090-0706; 50090-3987; 68071-4273; 72189-117; 71610-160; 70934-366; 68382-783; 70771-1114; 70771-1115
Synonyms Doxazosin | Novo-Doxazosin | Novo Doxazosin | Uriduct | Alfamedin | Apo-Doxazosin | Apo Doxazosin | Cardura | Cardular | Zoxan | Carduran | Carduran Neo | Neo, Carduran | Diblocin | Doxa-Puren | Doxa Puren | Doxacor | DoxaUro | Doxagamma | Doxamax | Doxatensa | Doxazomerck | Doxazosin AL | Doxazosin Apogepha | Doxazosin AZU | Doxazosin beta | Doxazosin findusFit | Doxazosin Heumann | Doxazosin Klast | Doxazosin Mesylate | Mesylate, Doxazosin | 1 (4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-((2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl)piperazine | Doxazosin Monohydrochloride | Monohydrochloride, Doxazosin | Doxazosin Stada | Doxazosin Von Ct | Ct, Doxazosin Von | Von Ct, Doxazosin | Doxazosin-ratiopharm | Doxazosin ratiopharm | ratio-Doxazosin | ratio Doxazosin | Doxazosina Ratiopharm | Ratiopharm, Doxazosina | Doxazosin-Wolff | Doxazosin Wolff | Doxazosina Alter | Doxazosina Cinfa | Doxazosina Combino Pharm | Doxazosina Geminis | Doxazosina Normon | Doxazosina Pharmagenus | Doxazosina Ur | Gen-Doxazosin | Gen Doxazosin | Jutalar | MTW-Doxazosin | MTW Doxazosin | Progandol Neo | UK-33274 | UK 33274 | UK33274
Chemical Information
Molecular Formula C23H25N5O5
CAS Registry Number 74191-85-8
SMILES COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4COC5=CC=CC=C5O4)N)OC
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Depressed level of consciousness17.02.04.0020.000727%
Depressed mood19.15.02.0010.000969%Not Available
Depression19.15.01.0010.001212%
Dermatitis23.03.04.002--Not Available
Diabetes mellitus14.06.01.001; 05.06.01.0010.000727%Not Available
Diarrhoea07.02.01.001--
Diplopia06.02.06.002; 17.17.01.0050.000727%Not Available
Discomfort08.01.08.003--Not Available
Disturbance in attention19.21.02.002; 17.03.03.001--
Diverticulitis11.01.07.003; 07.10.02.001--Not Available
Dizziness24.06.02.007; 17.02.05.003; 02.01.02.0040.006542%
Dizziness postural24.06.02.008; 17.02.05.004; 02.01.02.0050.000969%Not Available
Drug abuse19.07.02.0100.000316%Not Available
Drug hypersensitivity10.01.01.0010.005088%Not Available
Dry mouth07.06.01.0020.000969%
Dry skin23.03.03.001--
Dysarthria17.02.08.001; 19.19.03.0010.000727%
Dysgeusia17.02.07.003; 07.14.03.001--
Dyskinesia17.01.02.006--
Dyspepsia07.01.02.001--
Dyspnoea22.02.01.004; 02.01.03.0020.004119%
Dyspnoea exertional22.02.01.005; 02.01.03.0030.000485%Not Available
Dysuria20.02.02.0020.000727%
Ear pain04.03.01.003--
Eczema23.03.04.006--
Ejaculation failure21.03.01.003--Not Available
Electrocardiogram abnormal13.14.05.001--Not Available
Encephalopathy17.13.02.001--
Epididymitis21.09.02.001; 11.01.19.005--Not Available
Epilepsy17.12.03.002--Not Available
The 3th Page    First    Pre   3 4 5 6 7    Next   Last    Total 11 Pages